Neovacs SA (ALNEV.PA) Quote| Reuters.com
Edition:
United States

Neovacs SA (ALNEV.PA)

ALNEV.PA on Paris Stock Exchange

0.72EUR
24 Jun 2016
Change (% chg)

€-0.06 (-7.69%)
Prev Close
€0.78
Open
€0.67
Day's High
€0.73
Day's Low
€0.66
Volume
1,918,045
Avg. Vol
464,208
52-wk High
€1.56
52-wk Low
€0.64

ALNEV.PA

Chart for ALNEV.PA

About

Neovacs SA is a France-based company active in the biotechnology industry. It specializes in immunotherapy domain and providing treatment for autoimmune and inflammatory diseases. The Company researches and develops Kinoids, drug-candidates which aim to treat disease by including an antibody response in the patient. The Company... (more)

Overall

Beta: 0.56
Market Cap(Mil.): €30.67
Shares Outstanding(Mil.): 42.59
Dividend: --
Yield (%): --

Financials

  ALNEV.PA Industry Sector
P/E (TTM): -- 38.82 34.11
EPS (TTM): -0.19 -- --
ROI: -63.66 -5.72 14.23
ROE: -102.41 -4.83 15.46

BRIEF-Neovacs raises 8 million euros in capital increase

* Said on Wednesday it raised 8 million euros ($9.1 million) in capital increase

Jun 23 2016

BRIEF-Neovacs receives positive opinion from European Authorities for the clinical phase IIA study in dermatomyositis

* Receives positive opinion from European Authorities for the clinical phase IIA study in dermatomyositis Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Jun 06 2016

BRIEF-Neovacs launches capital increase of 8 million euros

* Launches a capital increase of 8 million euros ($8.90 million) with preferential subscription rights

Jun 01 2016

BRIEF-Neovacs and Stellar Biotechnologies sign JV agreement to create Neostell

* Neovacs and Stellar Biotechnologies sign joint venture agreement to create Neostell

May 12 2016

BRIEF-Stellar Biotechnologies and Neovacs sign JV

* Stellar Biotechnologies and Neovacs sign joint venture agreement to manufacture conjugated therapeutic vaccines with Stellar Klh(TM)

May 11 2016

BRIEF-Neovacs obtains FDA approval to extend its phase IIb clinical trial in Lupus to United States

* Obtains FDA approval to extend its phase IIb clinical trial in Lupus to United States Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Apr 28 2016

BRIEF-Neovacs gets approval of South Korean healthcare regulator for Phase IIb trial with Lupus

* Gets approval of South Korean healthcare regulator for Phase IIb trial with Lupus Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Apr 14 2016

BRIEF-Neovacs FY revenue rises to 1.2 million euro

* FY revenue 1.2 million euro ($1.32 million) versus 161,000 euro a year ago

Mar 07 2016

BRIEF-Neovacs associates Stellar Biotechnologies in its industrial project

* Signed a partnering agreement with American company Stellar Biotechnologies

Jan 21 2016

BRIEF-Neovacs secures EUR 5 mln from public funding program "Investments for the future"

* Says secures 5 million euros ($5.4 million) from the public funding program "Investments for the future" to support clinical and industrial development for the therapeutic vaccine INF Kinoïd

Jan 06 2016

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Reuters Investment Profile
$20.00
Provider : Wright Reports
$75.00
Provider : GlobalData
$300.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.